FLSM
ELVN icon

Frazier Life Sciences Management’s Enliven Therapeutics ELVN Stock Holding History

Frazier Life Sciences Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,050,483
Closed -$14.3M – 51
2023
Q3 		$14.3M Buy
1,050,483
+219,500
+26% +$3.7M 0.95% 26
2023
Q2 		$17M Hold
830,983
– – 1.01% 26
2023
Q1 		$18.2M Buy
+830,983
New +$16.9M 1.32% 22

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Life Sciences Management's ELVN Position: Q4 2023 in Review

Frazier Life Sciences Management sold out of Enliven Therapeutics (ELVN) in Q4 2023, closing a stake of 1,050,483 shares — an estimated $14.3M sold.

Frazier Life Sciences Management first reported a position in ELVN in Q1 2023 and held it in 3 quarters. The position peaked at $18.2M in Q1 2023. 62 funds tracked by Wall St. Rank hold ELVN as of Q4 2023.

  • Frazier Life Sciences Management reported no remaining Enliven Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,050,483 Enliven Therapeutics shares in Q4 2023, an estimated $14.3M.
  • Frazier Life Sciences Management first reported a position in Enliven Therapeutics in Q1 2023 and held it in 3 quarters.
  • Frazier Life Sciences Management's Enliven Therapeutics position peaked at $18.2M in Q1 2023.
  • 62 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2023.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.